Navigation Links
AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API

RANCHO CORDOVA, Calif., Aug. 11, 2011 /PRNewswire/ --  AMPAC Fine Chemicals LLC (AFC), a wholly-owned subsidiary of American Pacific Corporation (Nasdaq®: APFC), announced it has concluded an agreement with Chimerix, Inc. to validate at commercial scale the manufacturing process for the API in Chimerix's broad spectrum antiviral drug candidate, CMX001, which is being developed for the prevention and treatment of smallpox.  Chimerix will provide the investigational drug product under a Prime Contract with the U.S. Government Agency BARDA (Biomedical Advanced Research and Development Authority).  According to Kenneth I. Moch, President and Chief Executive Officer of Chimerix, "We look forward to working with AFC and BARDA to harness the full potential of CMX001 to address the biodefense threat represented by smallpox."

The validation campaign will be conducted in AFC's recently completed second semi-works unit.  The unit is located within a secured perimeter (security-alarmed fencing, cameras, controlled personnel access) segment of AFC on the DoD-regulated campus of Aerojet/GenCorp in Rancho Cordova.  "This facility offers a state of the art, remotely operated process plant which can safely run hydrogenations and hazardous chemical processes, while containing reactants and products with Occupational Exposure Limits (OELs) down to 0.5 µg/m3, combining two of the core strengths of AFC.  Equipment consists of 4 reactors (from 300-750 gal) and one 2.0 m2 Hastelloy filter-dryer.  The unit is ideally suited for the production of APIs required by companies like Chimerix," stated Larry Zeagler, Executive Director of Product Management for AFC.

"This agreement further solidifies our position as a supplier with world class cGMP manufacturing capabilities in the United States.  AFC is committed to maintaining the domestic assets and services needed by our customers to provide materials of critical importance to health and safety," stated Aslam Malik, President of AFC.

ABOUT AMPAC FINE CHEMICALS LLCAFC is a U.S.-based company with demonstrated capabilities in process development, scale-up, and cGMP-compliant commercial production of active pharmaceutical ingredients (APIs) and registered intermediates for pharmaceutical and biotechnology customers. Its specially engineered facilities and experienced staff allow AFC to safely produce highly energetic compounds at commercial scale. In addition, AFC's other technology platforms include production of highly potent compounds, continuous processes and industrial-scale chromatographic separation using simulated moving bed chromatography (SMB).  AFC's operations are located in Rancho Cordova, California and in La Porte, Texas.  Additional information about us can be obtained by visiting our web site at

ABOUT AMERICAN PACIFIC CORPORATIONAmerican Pacific Corporation (AMPAC) is a leading custom manufacturer of fine chemicals, specialty chemicals and propulsion products within its focused markets. We supply active pharmaceutical ingredients and advanced intermediates to the pharmaceutical industry. For the aerospace and defense industry we provide specialty chemicals used in solid rocket motors for space launch and military missiles. AMPAC also designs and manufactures liquid propulsion systems, valves and structures for space and missile defense applications. We produce clean agent chemicals for the fire protection industry, as well as electro-chemical equipment for the water treatment industry. Our products are designed to meet customer specifications and often must meet certain governmental and regulatory approvals. Additional information about us can be obtained by visiting our web site at

FORWARD-LOOKING STATEMENTSStatements contained in this press release that are not purely historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including without limitation statements regarding our agreement with Chimerix and the related future impacts. The inclusion of forward-looking statements should not be regarded as a representation by American Pacific Corporation and its affiliates (collectively, "American Pacific") that any of American Pacific's expectations will be achieved.  Actual results may differ materially from future results or outcomes expressed or implied by forward-looking statements set forth in this press release due to risks, uncertainties and other important factors inherent in American Pacific's business.  Factors that might cause actual results to differ include, but are not limited to, those included in the "Risk Factors" section of the Form 10-K for the year ended September 30, 2010 and filed by American Pacific Corporation with the U.S. Securities and Exchange Commission.  Readers of this press release are referred to the filings of American Pacific Corporation with the U.S. Securities and Exchange Commission, including the Form 10-K for Fiscal 2010, our Quarterly Report on Form 10-Q for the quarters ended March 31, 2011 and December 31, 2010, and our other filings with the Securities and Exchange Commission, for further discussion of these and other factors that could affect future results. The forward-looking statements contained in this press release are made as of the date hereof and American Pacific assumes no obligation to update for actual results or to update the reasons why actual results could differ materially from those projected in the forward-looking statements, except as required by law.  Technical Contact: William DuBay, Ph.D., Vice President,
Technology and Business DevelopmentAMPAC Fine Chemicals (800) 311 9668Investor Contact:Deanna Riccardi, Investor Relations ManagerAmerican Pacific Corporation (702) 735-2200

SOURCE American Pacific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. AMPAC Fine Chemicals Validates Continuous Extraction Process for API Manufacture
2. AMPAC Fine Chemicals Announces the Inauguration of the New cGMP Continuous Processing Development Facility
3. AMPAC Fine Chemicals Receives the California Pollution Prevention Challenge Award Two Consecutive Years
4. Reportlinker Adds Global Immunochemicals Industry
5. Mitsubishi Chemical Corporation Signs Memorandum of Understanding for Strategic Partnership With Genomatica for Sustainable Chemicals in Asia
6. Agrivida Announces Collaboration With Syngenta Ventures to Deliver Low-Cost Sugars for Cellulosic Biofuels and Biochemicals
7. Chemicals study pinpoints threat to workers lungs
8. AloeSafe™ Hand Sanitizer is Free From Toxic Chemicals
9. 21st Century Biochemicals Marks Its Third Consecutive Year on the Inc. 5000
10. Scotland Launches Chemicals Industry Partnerships To Propel $13 Billion Sector
11. Blue Marble Energy and Bionavitas Announce Partnership to Produce Industrial Biochemicals from Microalgae
Post Your Comments:
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... Conference in New York on Wednesday, December ... Helen Torley , president and CEO, will provide a corporate overview. ... New York at 1:00 p.m. ET/10:00 a.m. PT . ... investor relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015 About signature ... helps to identify and verify the identity of ... as the secure and accurate method of authentication ... particular individual because each individual,s signature is highly ... when dynamic signature of an individual is compared ...
(Date:10/29/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that it has ... as one of only three finalists for a ... and Growing" category. The Tekne Awards honor Minnesota ... technology innovation and leadership. iMedNet™ eClinical ...
(Date:10/29/2015)... Connecticut , October 29, 2015 ... a biometric authentication company focused on the growing ... smart wallet announces that StackCommerce, a leading marketplace ... be featuring the Wocket® smart wallet on StackSocial ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
Breaking Biology News(10 mins):